The Effect of Pirfenidone on Peyronie Plaques and Erectile Function in a Peyronie's Rat Model

Basit Öğe Kaydı
dc.authoriddursun, murat/0000-0001-9115-7203
dc.authoridÇevik, Gökhan/0000-0001-5221-5132
dc.authorwosiddursun, murat/C-6318-2019
dc.authorwosidÇevik, Gökhan/GZA-3993-2022
dc.contributor.authorCevik, Gokhan
dc.contributor.authorTozsin, Atinc
dc.contributor.authorTastekin, Ebru
dc.contributor.authorDursun, Murat
dc.contributor.authorAktoz, Tevfik
dc.contributor.authorKadioglu, Ates
dc.date.accessioned2024-06-12T10:51:58Z
dc.date.available2024-06-12T10:51:58Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: To investigate the anti-fibrotic effects of pirfenidone on Peyronie's disease in an experimental rat model with intracavernosal injection of TGF-ss and whether pirfenidone improves erectile function. Study Design: Experimental study. Place and Duration of the Study: Faculty of Medical Experimental Animals and Research Laboratory, Trakya University, from January to March 2021. Methodology: In this study, 27 male Sprague Dawley rats were used, and three groups were randomly identified. The rats in Group 1 served as the control group. Group 2 was not treated, and Group 3 was treated with pirfenidone therapy. The rats in Group 3 were administered pirfenidone 30 mg/kg/day by oral gavage, every day for four weeks, three weeks after the start of the experiment. At the end of seven weeks, a haemodynamic study was performed with cavernosal nerve stimulation to evaluate the erectile function, the rats were sacrificed, and the penile tissues were evaluated immunohistochemically. Results: MeICP/MIBP values were found to be higher in treated rats compared to rats in the untreated group but no statistically significant difference was found in MeICP/MIBP values between the control, Peyronie model, and treatment groups (p=0.25). According to the histopathological examination, the rate of fibrosis with H&E staining was mild (100%) in the control group, severe (100%) in the Peyronie group, and severe (87.5% severe and 12.5% moderate) in the Peyronie + treatment group. Conclusion: In the study, pirfenidone used in the treatment of Peyronie's disease had a positive effect on erectile function, though not considered statistically significant. It has been shown that it has no histopathological effect on Peyronie's plaques.en_US
dc.identifier.doi10.29271/jcpsp.2023.11.1217
dc.identifier.endpage1222en_US
dc.identifier.issn1022-386X
dc.identifier.issn1681-7168
dc.identifier.issue11en_US
dc.identifier.pmid37926870en_US
dc.identifier.scopus2-s2.0-85176320958en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1217en_US
dc.identifier.urihttps://doi.org/10.29271/jcpsp.2023.11.1217
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18551
dc.identifier.volume33en_US
dc.identifier.wosWOS:001150198900002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherColl Physicians & Surgeons Pakistanen_US
dc.relation.ispartofJcpsp-Journal Of The College Of Physicians And Surgeons Pakistanen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAnti-Fibrotic Agenten_US
dc.subjectErectile Functionen_US
dc.subjectExperimental Studyen_US
dc.subjectPeyronie's Diseaseen_US
dc.subjectPirfenidoneen_US
dc.subjectAnimal-Modelen_US
dc.subjectDiseaseen_US
dc.subjectProliferationen_US
dc.subjectFibroblastsen_US
dc.subjectColchicineen_US
dc.titleThe Effect of Pirfenidone on Peyronie Plaques and Erectile Function in a Peyronie's Rat Modelen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu